GENE ONLINE|News &
Opinion
Blog

2021-10-07|

BARDA Exercises $23.8 Million to Support Phase 3 Trial of Vedanta’s Encouraging Microbiome Therapy

by Manju Bhaskar
Share To
Recurrent Clostridium difficile infection (CDI) causes approximately half a million infections each year in the US, including up to 165,000 recurring infections and up to 45,000 deaths. Although several antibiotics are approved to treat CDI, recurrence occurs frequently and is a major cause of morbidity and mortality. Both CDI recurrence and infection by a variety of other bacterial species could encourage the spread of antibiotic resistance.

On October 5th, Vedanta Biosciences, a clinical-stage company, announced the positive results of the Phase 2 clinical trial of VE303, a potential new tool against CDI. VE303 is an orally administered, investigational live biotherapeutic product (LBP) in development for the prevention of recurrent CDI in patients at high risk for recurrence.

These encouraging outcomes have triggered a $23.8 million contract option from the Biomedical Advanced Research and Development Authority (BARDA) to support a Phase 3 clinical trial of VE303, which Vedanta plans to initiate in 2022.

GO Prime with only $1.49 now

LATEST
From Fabs to Labs: TSMC, Mayo Clinic, and the Next Wave of Bio-Digital Innovation in Phoenix
2025-07-17
AI-Powered Wound Care: 3D Digital TwinSkin Tech from Belgium to Asia
2025-07-16
XTANDI Plus Leuprolide Boosts Survival in Men at Risk of Prostate Cancer Relapse
2025-07-16
A Billion-Year Gap Closed With Lunar Meteorite Rewriting History
2025-07-16
A New Contender Rises: China’s Hengrui and Innovent Challenge Zepbound and Wegovy in Global Weight-Loss Drug Race
2025-07-16
Indian Kirana Stores Offer Trust-Building Lessons for the $638 Billion Global Pharmaceutical Industry
2025-07-16
Biotin Gummies Gain Popularity on Social Media Amid Debates Over Hair Growth Claims
2025-07-15
EVENT
2025-07-23
BIO Asia–Taiwan 2025
Taipei, Taiwan
2025-08-08
HEALTHY AGEING TECH SHOW
Taipei, Taiwan
2025-08-09
MEDINFO 2025
Taipei, Taiwan
2025-09-03
BIO ASIA PACIFIC 2025
Bangkok, Thailand
2025-09-10
BIOHK 2025
Hong Kong
2025-10-01
Medical Japan 2025
Osaka, Japan
Scroll to Top